Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

An FDA advisory committee on Friday voted 8 to 4 in favor of Japan-based Seikagaku's condoliase injection for the treatment ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, ...

Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...

Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it ...

China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The ...

City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...